A Study to Evaluate the Safety and Tolerability of AB154 in Participants With Advanced Malignancies

Conditions:   Non-small Cell Lung Cancer;   Squamous Cell Carcinoma of the Head and Neck;   Renal Cell Carcinoma;   Breast Cancer;   Colorectal Cancer;   Melanoma;   Bladder Cancer;   Ovarian Cancer;   Endometrial Cancer;   Merkel Cell Carcinoma;   GastroEsophageal Cancer
Interventions:   Drug: AB154;   Drug: AB122
Sponsor:   Arcus Biosciences, Inc.
Not yet recruiting

https://ift.tt/2P6b9y5